// App-Quantinova.ai

AB0258 (2018) : Impact of controlling disease activity on regaining normal physical function, and achieving no or limited pain in patients with rheumatoid arthritis treated with baricitinib

Researchers

Presenter

  • K. de Vlam

Principal Investigators

  • B. Fautrel

  • M. van de Laar

  • B.W. Kirkham

  • R. Alten

  • K.V. Beneden

  • F. de Leonardis

  • P. Lopez-Romero

  • C. Gaich

  • A. Quebe

  • A. Cardoso

  • R. Fleischmann

  • P. Emery

Medical Centers

  • Department of Musculoskeletal Sciences, University Hospital Leuven, Leuven, Belgium

  • Department of Anesthesiology, La Pitie-Salpetriere Hospital, Paris, France

  • Medisch Spectrum Twente, Enschede, Netherlands

  • Rheumatology Department, Guy’s and St Thomas’ NHS Foundation Trust, London, UK

  • Schlosspark Clinic, Berlin, Germany

  • Eli Lilly and Company, Brussels, Belgium

  • Eli Lilly and Company, Swiss, Switzerland

  • Eli Lilly and Company, Madrid, Spain

  • Eli Lilly and Company, Indianapolis, IN

  • Metroplax Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX

  • Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds & NIHR Leeds Biomedical Research Centre, Leeds, United Kingdom

Locations

  • Belgium

  • France

  • Netherlands

  • United Kingdom

  • Germany

  • Switzerland

  • Spain

  • United States

Companies

  • Eli Lilly and Compan

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Rheumatoid arthritis

Biomarkers

  • Malondialdehyde

Drug/Treatment

  • Baricitinib

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • NCT01710358

  • NCT01711359

Sponsors

  • Abbvie

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved